Phenotypes Associated with This Genotype

Genotype
MGI:3690081

tg1

• Allelic Composition: Tg(Myh6-EP300)21Csk/0
• Genetic Background: C57BL/6-Tg(Myh6-EP300)21Csk

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

decreased susceptibility to xenobiotic induced morbidity/mortality ( J:110550 )

• mutants treated with doxorubicin, an anti-tumor agent with cardiotoxicity, show a higher survival rate

premature death ( J:110549 )

• mutants are prone to premature death after 20 weeks of age and show lower survival rates than wild-type at 42 weeks of age

cardiovascular system

abnormal myocardial fiber morphology ( J:110549 )

• hearts show hypertrophy of individual myocytes but no evidence of increased fibrosis, myofibrillar disarray, or inflammatory changes

• cross-sectional myocardial-cell diameter is increased

cardiac hypertrophy ( J:110549 )

• hearts show an increase in heart weight-to-body weight ratio

dilated heart left ventricle ( J:110549 )

• show dilatation of the left ventricles without a significant increase in wall thickness at 24 weeks of age

decreased heart left ventricle muscle contractility ( J:110549 )

• at 24 weeks of age, show depressed fractional shortening and increased cavity diameter of the left ventricles but no differences in left ventricular wall thickness and heart rate

congestive heart failure ( J:110549 )

• develop heart failure after 20 weeks of age

muscle

abnormal myocardial fiber morphology ( J:110549 )

• hearts show hypertrophy of individual myocytes but no evidence of increased fibrosis, myofibrillar disarray, or inflammatory changes

• cross-sectional myocardial-cell diameter is increased

decreased heart left ventricle muscle contractility ( J:110549 )

• at 24 weeks of age, show depressed fractional shortening and increased cavity diameter of the left ventricles but no differences in left ventricular wall thickness and heart rate

homeostasis/metabolism

decreased susceptibility to xenobiotic induced morbidity/mortality ( J:110550 )

• mutants treated with doxorubicin, an anti-tumor agent with cardiotoxicity, show a higher survival rate

decreased physiological sensitivity to xenobiotic ( J:110550 )

• mutants treated with doxorubicin, an anti-tumor agent with cardiotoxicity, show more preserved left ventricular function, and no myocardial cell apoptosis compared to wild-type, indicating prevention of acute heart failure

growth/size/body

cardiac hypertrophy ( J:110549 )

• hearts show an increase in heart weight-to-body weight ratio